Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in ...
NEW YORK, NY / ACCESS Newswire / November 14, 2025 / A new kind of global contest is unfolding, one that is not powered by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback